The in vitro and in vivo potential of the tool compound S63845 was explored in pre-clinical studies in haematological malignancies, such as MM, AML, CML, and c-MYC-driven Burkitt lymphoma [171]. This evidence concerns the gene MYC and acute myeloid leukemia.